Product Images Amlodipine And Atorvastatin

This text contains information about a medication called "Amlodipine and Atorvastatin Tablets, USP" that consists of 10mg amlodipine (as amlodipine besylate, USP) and 139mg atorvastatin (as atorvastatin calcium, USP). The recommended dosage and usage instructions are stated in the accompanying prescription information. The package should be stored at controlled room temperature. The manufacturer is Alembic Pharmaceuticals Limited, and the address is provided in Gujarat, India. The NDC number for this medication is 46708-762-30.*

This text appears to be a description of a medication containing Amlodipine and Atorvastatin tablets, USP. The tablets contain 10mg Amlodipine (as Amlodipine besilate, USP), 139 mg Amlodipine and 20mg Atorvastatin (as Atorvastatin calcium trihydrate, USP), and 207 mg Atorvastatin. The dosage and usage details should be followed as per the accompanying prescribing information. The medication is from the company Actavis Limited, with an address in Panchkula, India. The tablets are packaged in a bottle containing 30 tablets. Storage instructions indicate to store at temperatures between 16-40 degrees Celsius and in a USP controlled room temperature not exceeding 26 degrees Celsius. The medication is available by prescription only.*

This text is a description of a medication package containing tablets with 25 mg amlodipine and 10 mg atorvastatin. The tablets are stated to be child-resistant. The manufacturing company is Alembic Pharmaceutical Limited in India. The package contains 30 tablets and must be stored at a temperature range of 15°C to 30°C. Additional information on dosage and use is available in the prescribing information.*

This text provides information about a medication containing Amlodipine and Atorvastatin in tablet form with a dosage of 2.5mg/20mg. The text includes the name of the manufacturer, Alembic Pharmaceuticals, along with their address and contact details. It also mentions the NDC code for the medication. The text states that the medication is prescription-only and comes in a package with accompanying prescribing information.*

This text provides information about a medication called "Amlodipine and Atorvastatin Tablets, USP" containing 2.5 mg of amlodipine and 0 mg of atorvastatin. It includes dosage instructions and contact details for the manufacturer, Aot Pharmaceuticals Limited. Additionally, it specifies storage instructions and provides an NDC code for identification.*

This text appears to be a description related to a medication called "Amlodipine and Atorvastatin Tablets, USP." It includes dosage information, manufacturer details, and a prescribing reminder. The tablets are advised to be stored at room temperature, and the prescription is for 30 tablets. The manufacturer is listed as Alembic Pharmaceuticals Limited.*

This text provides information about a medication containing Amlodipine and Atorvastatin in tablet form, with a dosage of 5 mg/40 mg. It mentions the pharmaceutical company Alambic, the recommended storage conditions, a reference to controlled room temperature, and contact details for Apt Pharma Limited. There is a reference to a prescribing form and the packaging being child-resistant. Additional dosage instructions and details are advised to be found on the accompanying prescribing information. The text also includes the address of Apt Pharma Limited in Panchkula, India.*

This text seems to provide information on a clinical trial comparing Atorvastatin to a placebo in terms of their effects. It mentions different values and results of the trial, such as HR=0.64 (0.5 to 0.83) and p=0.0005, as well as a timeline of years for the study. This information can be useful for understanding the efficacy of Atorvastatin compared to a placebo treatment.*

This is a statistical outcome showing the cumulative hazard (%) over a four-year follow-up period for placebo and Atorvastatin. The hazard ratio (HR) for Atorvastatin compared to placebo is 0.63 with a confidence interval of 0.48 to 0.83 and a p-value of 0.001, indicating a significant difference in the risk of primary endpoint events between the two groups. The chart displays the time to the first primary endpoint event throughout the four years of observation.*

This text provides statistical data regarding the percentage of subjects experiencing an event with different doses of Atorvastatin (10 mg and 80 mg). It shows a hazard ratio (HR) of 0.78 with a confidence interval of 0.69 to 0.89 and a p-value of 0.0002. The analysis also includes the time to the first major cardiovascular endpoint over the course of several years.*